BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24171212)

  • 1. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
    Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
    Kowalczyk M; Banach M; Rysz J
    J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
    BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.
    Hetzel D; Strauss W; Bernard K; Li Z; Urboniene A; Allen LF
    Am J Hematol; 2014 Jun; 89(6):646-50. PubMed ID: 24639149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
    Kochhar PK; Kaundal A; Ghosh P
    J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
    Stein J; Dignass A; Chow KU
    Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron sucrose--an effective and attractive modality for perioperative anaemia management.
    Froessler B; Papendorf D
    Anaesth Intensive Care; 2010 Sep; 38(5):960-2. PubMed ID: 20865896
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
    Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
    Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
    Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
    Intern Med; 2012; 51(17):2375-8. PubMed ID: 22975552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.
    Vadhan-Raj S; Ford DC; Dahl NV; Bernard K; Li Z; Allen LF; Strauss WE
    Am J Hematol; 2016 Feb; 91(2):E3-5. PubMed ID: 26572233
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
    Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Potthoff SA; Münch HG
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon adverse effect of a common medication.
    Moore KL; Kildahl-Andersen O; Kildahl-Andersen R; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2013 Jan; 133(2):165. PubMed ID: 23344600
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous iron sucrose: an alternative for oral iron in pregnancy with iron deficiency anemia.
    Shi Q; Li J; Yao Q; Mi C; Yang J; Xing A
    Ann Hematol; 2015 Mar; 94(3):523-5. PubMed ID: 25123238
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.
    Reinisch W; Staun M; Bhandari S; Muñoz M
    J Crohns Colitis; 2013 Jul; 7(6):429-40. PubMed ID: 22917870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.